Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Merus Labs International in a research note issued on Thursday, March 27th. HC Wainwright analyst A. He anticipates that the specialty pharmaceutical company will post earnings of ($0.13) per share for the year.
Merus Labs International Stock Performance
Merus Labs International has a 1-year low of C$0.95 and a 1-year high of C$1.76. The stock has a fifty day simple moving average of C$1.65.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Read More
- Five stocks we like better than Merus Labs International
- How to Use Stock Screeners to Find Stocks
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- 5 discounted opportunities for dividend growth investors
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
